Oura Health is signaling it's ready for the public markets. CEO Tom Hale told The New York Times the health-tracking ring maker has hit all the key metrics for an IPO, even as reports swirl around a massive $11 billion funding round that would cement Oura's position as the dominant player in wearable health tech.
The wearable health market just got a major validation signal. Oura Health CEO Tom Hale is openly discussing taking the Finnish health-tracking company public, telling The New York Times that an IPO is 'certainly an option' after the company hit critical scale milestones.
'We've certainly hit the thresholds of size, trajectory, scale and growth,' Hale said in the interview. 'We could go public. Is that in our plans? It's certainly an option. And when the moment is right, we'll let everyone know.'
The timing isn't coincidental. TechCrunch previously reported that Oura is in talks to raise $875 million in Series E funding at an $11 billion valuation - a massive jump that would place the company among the most valuable private health tech companies globally. While Hale didn't address the funding reports directly, his IPO comments suggest Oura is positioning itself for major capital markets activity.
The numbers back up the confidence. Oura expects to generate $1 billion in revenue this year, effectively doubling its 2024 performance. That growth trajectory puts the company in rare territory for hardware-focused health tech companies, most of which struggle to scale beyond niche markets.
Oura's success comes as the broader wearable health market explodes. While Apple dominates with the Apple Watch and fitness tracking features, Oura carved out a premium niche with its ring form factor and focus on sleep and recovery metrics. The company's approach resonated particularly well with health-conscious consumers willing to pay premium prices for detailed biometric insights.
But growth brings scrutiny, especially around data privacy. Hale addressed concerns about Oura's participation in government data-sharing programs initiated during the Trump administration, emphasizing user control over their health information.
'It's not, "Oh, I'm now sharing my data with the Trump administration." Like, no,' Hale explained. He stressed that 'the privacy and security of your data is nonnegotiable,' particularly when personal health data 'could be used in any way against you.'
The privacy stance reflects broader industry tensions as health tech companies navigate regulatory requirements while protecting user trust. Meta and Google have faced similar challenges integrating health features into their platforms, often hitting privacy roadblocks that limit functionality.
For Oura, the IPO consideration comes at a critical inflection point. The company needs to prove it can maintain growth rates while expanding beyond its core ring product. Competitors like Samsung and Fitbit (owned by Google) continue pushing into sleep and recovery tracking, Oura's key differentiators.
The potential $11 billion valuation also raises questions about sustainability in a market where hardware margins remain challenging. Unlike software companies that can scale without proportional cost increases, Oura must manage supply chains, manufacturing, and physical product development - all while competing against tech giants with deeper pockets.
Market conditions for health tech IPOs remain mixed. While investors show appetite for proven growth stories, recent public offerings in adjacent sectors have faced volatility as growth rates normalize post-pandemic.
Hale's personal commitment to the product - he mentioned maintaining 7.5 hours of sleep nightly, presumably tracked by his own ring - signals the kind of founder-led conviction investors typically favor in IPO candidates.
Oura's IPO signals represent more than just another tech company going public - they mark the maturation of consumer health tracking from niche gadget to mainstream necessity. With $1 billion in projected revenue and an $11 billion potential valuation, Oura has proven that focused health hardware can compete alongside tech giants. The question now is whether public market investors will value consistent growth in a hardware business the same way they've rewarded software platforms. For the broader wearable health sector, Oura's next moves could determine whether specialized health devices remain viable against integrated ecosystem plays from Apple and Google.
